Clinical Trial Update: Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045) [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing immunogenicity and safety of ZOSTAVAX given intramuscularly or subcutaneously in adults aged 50 and older; study completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Zostavax (Varicella zoster vaccine live)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Herpes Zoster | Phase 3 | Status: COMPLETED | Results posted: 2017-11-20